Shanghai General Hospital and Shanghai Jiao Tong University School of Medicine have announced an innovative clinical trial exploring a combined surgical and oncological approach for thymic epithelial tumors with pleural metastasis or recurrence. This newly registered study aims to improve treatment outcomes for individuals facing these challenging conditions.
In this article
What changed?
As of January 10, 2026, a new study has been registered to investigate the potential synergy between advanced surgical techniques and hyperthermic intrathoracic chemotherapy (HITHOC). While the trial status is currently listed as “Not yet recruiting,” it represents a significant step forward in developing therapies targeting pleural metastasis associated with thymic epithelial tumors.
Who is affected?
This clinical trial is targeted at patients diagnosed with thymic epithelial tumors, including thymoma and thymic carcinoma, that exhibit pleural involvement through metastasis or recurrence. Clinicians, regulatory teams, and medical device developers may find the study highly relevant, as it evaluates procedure efficacy and combination therapy outcomes in a controlled environment.
Clinical trial details
The trial will assess a new treatment protocol combining two key components:
- Electrocautery resection: This procedure involves surgical removal of pleural metastases using electrocautery techniques during an extended thymectomy, aiming for precise lesion excision with minimal damage to surrounding tissues.
- HITHOC application: Following resection, patients will undergo two cycles of hyperthermic intrathoracic chemotherapy. This involves the localized application of heated chemotherapeutic agents to the thoracic cavity, designed to target residual cancer cells and improve effectiveness while reducing systemic toxicity.
The trial’s sponsor, Shanghai General Hospital, partnered with Shanghai Jiao Tong University School of Medicine, showcases its commitment to studying complex oncological cases using cutting-edge interventions. Once patient recruitment begins, further details on eligibility criteria and enrollment timelines are expected to become available.
FAQ
- What is HITHOC?
Hyperthermic intrathoracic chemotherapy (HITHOC) involves administering heated chemotherapy drugs directly into the thoracic cavity to target malignant cells locally. - Who can participate in this trial?
Patients diagnosed with thymic epithelial tumors involving pleural metastasis or recurrence may be eligible. Specific inclusion and exclusion criteria will be available when recruitment begins. - Where is the study being conducted?
The trial is sponsored by Shanghai General Hospital in collaboration with Shanghai Jiao Tong University School of Medicine. - When will recruitment start?
The trial is currently listed as “Not yet recruiting.” Updates on recruitment timelines will follow.
Conclusion
This new trial combines electrocautery-facilitated surgical resection with HITHOC to address thymic epithelial tumors with pleural spread. If successful, this approach could establish a new standard for managing these advanced oncological cases, offering hope for improved outcomes. Medical professionals and quality teams should keep abreast of further updates on this study.
Disclaimer
This article is for informational purposes only and does not constitute legal or medical advice. Readers should consult appropriate professionals for specific guidance.
Full announcement link
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07328074?term=medical+device